{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:09:44Z","timestamp":1789639784581,"version":"4.0.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82260957"],"award-info":[{"award-number":["No. 82260957"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82460918"],"award-info":[{"award-number":["No. 82460918"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82274610"],"award-info":[{"award-number":["No. 82274610"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guizhou Higher Education Institutions Chinese Medicine and Ethnic Medicine to Prevent and Control Tumor Medical Translational Engineering Research Center of Guizhou Education and Technology [2023]","award":["No. 037"],"award-info":[{"award-number":["No. 037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Background: Previous observational studies have suggested a potential association between Epstein-Barr virus (EBV) infection and the development of multiple myeloma (MM), but this relationship is not clear. Therefore, we conducted a systematic Mendelian randomization (MR) analysis to investigate the causal relationship between EBV infection and the risk of MM, while exploring the possible mediating role of immune cells in this association. Methods: The study first conducted a two-sample MR analysis using the MM R11 dataset from the FinnGen Consortium to evaluate the causal relationship between five EBV infection-related antibodies (AEB-IgG, EA-D, EBNA-1, VCA-p18, and ZEBRA) and MM, with validation in the MM R10 dataset. A reverse MR analysis was then performed. For significant results, multivariable MR (MVMR) was used to adjust for the effects of confounding risk factors. Next, a two-step MR mediation analysis was applied to investigate the potential mediating role of 731 immune cell types between positive exposure and MM. Multiple sensitivity analyses were conducted to assess the robustness of the findings. Results: A two-sample MR study found that EBNA-1 antibodies (OR\u2009=\u20091.36, 95% CI: 1.06\u20131.73; <jats:italic>P<\/jats:italic>\u2009=\u20090.015) were associated with an increased risk of MM, with similar results observed in the FinnGen Consortium R10 replication study. Although the association did not remain statistically significant after false discovery rate (FDR) adjustment (P_fdr\u2009=\u20090.075), further adjustment for relevant confounders using multivariable MR (MVMR) demonstrated that EBNA-1 antibodies (OR\u2009=\u20091.33, 95% CI: 1.01\u20131.75; <jats:italic>P<\/jats:italic>\u2009=\u20090.041) were still significantly associated with an increased risk of MM. Reverse MR analysis indicated no causal effect of MM on EBV-related antibodies. A two-sample MR analysis involving 731 immune cell phenotypes identified 27 potential mediating cell types. Ultimately, two-step MR confirmed that HLA-DR on myeloid dendritic cells (HLA-DR\u207a mDC) serves as a mediating factor, with EBNA-1 antibodies downregulating HLA-DR\u207a mDC, thereby increasing MM risk. Multiple sensitivity analyses supported the robustness of these findings. Conclusion: The findings of this study suggest that EBNA-1 antibodies may increase the risk of MM by downregulating HLA-DR\u207a mDC. This indicates that chronic EBV infection may contribute to an elevated risk of MM. We hope these results provide new insights for future research on the prevention and treatment of MM.<\/jats:p>","DOI":"10.1038\/s41598-025-90479-1","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:07:49Z","timestamp":1740139669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genetic evidence identifies a causal relationship between EBV infection and multiple myeloma risk"],"prefix":"10.1038","volume":"15","author":[{"given":"Jian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changpu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"90479_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972. https:\/\/doi.org\/10.1182\/blood-2007-10-078022 (2008).","journal-title":"Blood"},{"key":"90479_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5 (2014).","journal-title":"Lancet Oncol."},{"key":"90479_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"Cancer J. Clin."},{"key":"90479_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422 (2024).","journal-title":"Am. J. Hematol."},{"key":"90479_CR5","doi-asserted-by":"publisher","first-page":"2314322","DOI":"10.1080\/15384047.2024.2314322","volume":"25","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells. Cancer Biol. Ther. 25, 2314322. https:\/\/doi.org\/10.1080\/15384047.2024.2314322 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"90479_CR6","doi-asserted-by":"publisher","first-page":"122662","DOI":"10.1016\/j.biomaterials.2024.122662","volume":"311","author":"X Dong","year":"2024","unstructured":"Dong, X. et al. Sonocatalytic oncolysis microbiota curb intrinsic microbiota lactate metabolism and blockade CD24-Siglec10 immune escape to revitalize immunological surveillance. Biomaterials 311, 122662. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122662 (2024).","journal-title":"Biomaterials"},{"key":"90479_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","volume":"21","author":"P Neri","year":"2024","unstructured":"Neri, P. et al. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat. Rev. Clin. Oncol. 21, 590\u2013609. https:\/\/doi.org\/10.1038\/s41571-024-00913-y (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"90479_CR8","doi-asserted-by":"publisher","unstructured":"Dokanei, S., Minai-Tehrani, D., Moghoofei, M. & Rostamian, M. Investigating the relationship between Epstein-Barr virus infection and gastric cancer: A systematic review and meta-analysis. Health Sci. Rep. 7, e 1976 (2024) https:\/\/doi.org\/10.1002\/hsr2.1976","DOI":"10.1002\/hsr2.1976"},{"key":"90479_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35212","author":"R Jain","year":"2024","unstructured":"Jain, R. et al. Detection of anti-EBV TCR CDR3s associated with better outcomes for EBV-positive, Ugandan cases of Burkitt lymphoma. Int. J. Cancer. https:\/\/doi.org\/10.1002\/ijc.35212 (2024).","journal-title":"Int. J. Cancer"},{"key":"90479_CR10","doi-asserted-by":"publisher","first-page":"e2308765","DOI":"10.1002\/advs.202308765","volume":"11","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. VLDL and LDL subfractions enhance the risk stratification of individuals who underwent Epstein-Barr Virus-based screening for nasopharyngeal carcinoma: a Multicenter Cohort Study. Adv. Sci. (Weinheim Baden-Wurttemberg Germany). 11, e2308765. https:\/\/doi.org\/10.1002\/advs.202308765 (2024).","journal-title":"Adv. Sci. (Weinheim Baden-Wurttemberg Germany)"},{"key":"90479_CR11","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1128\/jvi.00468-11","volume":"85","author":"S Leonard","year":"2011","unstructured":"Leonard, S. et al. Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin\u2019s lymphoma. J. Virol. 85, 9568\u20139577. https:\/\/doi.org\/10.1128\/jvi.00468-11 (2011).","journal-title":"J. Virol."},{"key":"90479_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4103\/0377-4929.91504","volume":"54","author":"MH Sadeghian","year":"2011","unstructured":"Sadeghian, M. H. et al. The association of Epstein-Barr virus infection with multiple myeloma. Indian J. Pathol. Microbiol. 54, 720\u2013724. https:\/\/doi.org\/10.4103\/0377-4929.91504 (2011).","journal-title":"Indian J. Pathol. Microbiol."},{"key":"90479_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/10428194.2016.1190976","volume":"58","author":"G Mameli","year":"2017","unstructured":"Mameli, G. et al. Epstein-Barr virus infection is associated to patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Leuk. Lymphoma. 58, 466\u2013469. https:\/\/doi.org\/10.1080\/10428194.2016.1190976 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"90479_CR14","doi-asserted-by":"publisher","unstructured":"Xia, B. et al. Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma. Biosci. Rep. 39 https:\/\/doi.org\/10.1042\/bsr20190284 (2019).","DOI":"10.1042\/bsr20190284"},{"key":"90479_CR15","doi-asserted-by":"publisher","first-page":"e0008821","DOI":"10.1128\/jvi.00088-21","volume":"95","author":"F Lu","year":"2021","unstructured":"Lu, F. et al. Defective Epstein-Barr Virus genomes and atypical viral gene expression in B-Cell lines derived from multiple myeloma patients. J. Virol. 95, e0008821. https:\/\/doi.org\/10.1128\/jvi.00088-21 (2021).","journal-title":"J. Virol."},{"key":"90479_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/10428194.2023.2172982","volume":"64","author":"S Li","year":"2023","unstructured":"Li, S. et al. Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma. Leuk. Lymphoma. 64, 835\u2013845. https:\/\/doi.org\/10.1080\/10428194.2023.2172982 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"90479_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer. 4, 757\u2013768. https:\/\/doi.org\/10.1038\/nrc1452 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"90479_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3181\/00379727-179-42108","volume":"179","author":"R Glaser","year":"1985","unstructured":"Glaser, R. et al. Changes in Epstein-Barr virus antibody titers associated with aging. Proc. Soc. Exp. Biol. Med. 179, 352\u2013355. https:\/\/doi.org\/10.3181\/00379727-179-42108 (1985).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"90479_CR19","doi-asserted-by":"publisher","first-page":"10912","DOI":"10.1038\/s41598-023-37502-5","volume":"13","author":"MI Hofstee","year":"2023","unstructured":"Hofstee, M. I. et al. Cytomegalovirus and Epstein-Barr virus co-infected young and middle-aged adults can have an aging-related T-cell phenotype. Sci. Rep. 13, 10912. https:\/\/doi.org\/10.1038\/s41598-023-37502-5 (2023).","journal-title":"Sci. Rep."},{"key":"90479_CR20","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.2169\/internalmedicine.50.4892","volume":"50","author":"S Sasaki","year":"2011","unstructured":"Sasaki, S. et al. Plasmablastic extramedullary plasmacytoma associated with Epstein-Barr virus arising in an immunocompetent patient with multiple myeloma. Intern. Med. 50, 2615\u20132620. https:\/\/doi.org\/10.2169\/internalmedicine.50.4892 (2011).","journal-title":"Intern. Med."},{"key":"90479_CR21","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/s0140-6736(04)16260-0","volume":"363","author":"DA Lawlor","year":"2004","unstructured":"Lawlor, D. A., Davey Smith, G., Kundu, D., Bruckdorfer, K. R. & Ebrahim, S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet (London England). 363, 1724\u20131727. https:\/\/doi.org\/10.1016\/s0140-6736(04)16260-0 (2004).","journal-title":"Lancet (London England)"},{"key":"90479_CR22","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1161\/circulationaha.117.028307","volume":"135","author":"N Sattar","year":"2017","unstructured":"Sattar, N. & Preiss, D. Reverse causality in Cardiovascular Epidemiological Research: more common than imagined? Circulation 135, 2369\u20132372. https:\/\/doi.org\/10.1161\/circulationaha.117.028307 (2017).","journal-title":"Circulation"},{"key":"90479_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/aje\/kwm165","volume":"166","author":"Z Fewell","year":"2007","unstructured":"Fewell, Z., Davey Smith, G. & Sterne, J. A. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am. J. Epidemiol. 166, 646\u2013655. https:\/\/doi.org\/10.1093\/aje\/kwm165 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"90479_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1055-9965.Epi-17-1177","volume":"27","author":"J Yarmolinsky","year":"2018","unstructured":"Yarmolinsky, J. et al. Causal inference in Cancer Epidemiology: what is the role of mendelian randomization? Cancer Epidemiol. Biomarkers Prevention: Publication Am. Association Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 27, 995\u20131010. https:\/\/doi.org\/10.1158\/1055-9965.Epi-17-1177 (2018).","journal-title":"Cancer Epidemiol. Biomarkers Prevention: Publication Am. Association Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"90479_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12916-022-02246-y","volume":"20","author":"G Markozannes","year":"2022","unstructured":"Markozannes, G. et al. Systematic review of mendelian randomization studies on risk of cancer. BMC Med. 20, 41. https:\/\/doi.org\/10.1186\/s12916-022-02246-y (2022).","journal-title":"BMC Med."},{"key":"90479_CR26","doi-asserted-by":"publisher","first-page":"104991","DOI":"10.1016\/j.ebiom.2024.104991","volume":"100","author":"J Yarmolinsky","year":"2024","unstructured":"Yarmolinsky, J. et al. Association between circulating inflammatory markers and adult cancer risk: a mendelian randomization analysis. EBioMedicine 100, 104991. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104991 (2024).","journal-title":"EBioMedicine"},{"key":"90479_CR27","doi-asserted-by":"publisher","unstructured":"Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. Bmj 362, k601 (2018). https:\/\/doi.org\/10.1136\/bmj.k601","DOI":"10.1136\/bmj.k601"},{"key":"90479_CR28","doi-asserted-by":"publisher","first-page":"ofaa450","DOI":"10.1093\/ofid\/ofaa450","volume":"7","author":"G Butler-Laporte","year":"2020","unstructured":"Butler-Laporte, G. et al. Genetic determinants of antibody-mediated Immune responses to infectious diseases agents: a genome-wide and HLA Association Study. Open. Forum Infect. Dis. 7, ofaa450. https:\/\/doi.org\/10.1093\/ofid\/ofaa450 (2020).","journal-title":"Open. Forum Infect. Dis."},{"key":"90479_CR29","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","volume":"52","author":"V Orr\u00f9","year":"2020","unstructured":"Orr\u00f9, V. et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat. Genet. 52, 1036\u20131045. https:\/\/doi.org\/10.1038\/s41588-020-0684-4 (2020).","journal-title":"Nat. Genet."},{"key":"90479_CR30","doi-asserted-by":"publisher","unstructured":"Julian, T. H. et al. Phenome-wide mendelian randomisation analysis identifies causal factors for age-related macular degeneration. Elife 12 https:\/\/doi.org\/10.7554\/eLife.82546 (2023).","DOI":"10.7554\/eLife.82546"},{"key":"90479_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/aje\/kwr026","volume":"173","author":"TM Palmer","year":"2011","unstructured":"Palmer, T. M. et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in mendelian randomization analyses. Am. J. Epidemiol. 173, 1392\u20131403. https:\/\/doi.org\/10.1093\/aje\/kwr026 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"90479_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jid.2019.03.1138","volume":"139","author":"A Budu-Aggrey","year":"2019","unstructured":"Budu-Aggrey, A. & Paternoster, L. Research Techniques made simple: using genetic variants for randomization. J. Invest. Dermatol. 139, 1416\u20131421e1411. https:\/\/doi.org\/10.1016\/j.jid.2019.03.1138 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"90479_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304\u2013314. https:\/\/doi.org\/10.1002\/gepi.21965 (2016).","journal-title":"Genet. Epidemiol."},{"key":"90479_CR34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ajhg.2021.05.014","volume":"108","author":"H Xue","year":"2021","unstructured":"Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. Am. J. Hum. Genet. 108, 1251\u20131269. https:\/\/doi.org\/10.1016\/j.ajhg.2021.05.014 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"90479_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12916-023-02982-9","volume":"21","author":"K Yu","year":"2023","unstructured":"Yu, K. et al. Assessment of bidirectional relationships between brain imaging-derived phenotypes and stroke: a mendelian randomization study. BMC Med. 21, 271. https:\/\/doi.org\/10.1186\/s12916-023-02982-9 (2023).","journal-title":"BMC Med."},{"key":"90479_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","volume":"92","author":"KI Avgerinos","year":"2019","unstructured":"Avgerinos, K. I., Spyrou, N., Mantzoros, C. S. & Dalamaga, M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism 92, 121\u2013135. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.001 (2019).","journal-title":"Metabolism"},{"key":"90479_CR37","doi-asserted-by":"publisher","first-page":"e1010738","DOI":"10.1371\/journal.ppat.1010738","volume":"18","author":"CB Karsten","year":"2022","unstructured":"Karsten, C. B. et al. Evolution of functional antibodies following acute Epstein-Barr virus infection. PLoS Pathog. 18, e1010738. https:\/\/doi.org\/10.1371\/journal.ppat.1010738 (2022).","journal-title":"PLoS Pathog"},{"key":"90479_CR38","doi-asserted-by":"publisher","unstructured":"Epstein, M. A., Achong, B. G. &  Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet (London England) 1, 702\u2013703 https:\/\/doi.org\/10.1016\/s0140-6736(64)91524-7 (1964).","DOI":"10.1016\/s0140-6736(64)91524-7"},{"key":"90479_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell, P. J. Epstein-Barr Virus and Cancer. Annu. Rev. Pathol. 14, 29\u201353. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-013023 (2019).","journal-title":"Annu. Rev. Pathol."},{"key":"90479_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"Yang, J., Liu, Z., Zeng, B., Hu, G. & Gan, R. Epstein-Barr virus-associated gastric cancer: a distinct subtype. Cancer Lett. 495, 191\u2013199. https:\/\/doi.org\/10.1016\/j.canlet.2020.09.019 (2020).","journal-title":"Cancer Lett."},{"key":"90479_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bios.2011.09.025","volume":"30","author":"G Garai-Ibabe","year":"2011","unstructured":"Garai-Ibabe, G. et al. Label free and amplified detection of cancer marker EBNA-1 by DNA probe based biosensors. Biosens. Bioelectron. 30, 272\u2013275. https:\/\/doi.org\/10.1016\/j.bios.2011.09.025 (2011).","journal-title":"Biosens. Bioelectron."},{"key":"90479_CR42","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/cas.13954","volume":"110","author":"T Kanda","year":"2019","unstructured":"Kanda, T., Yajima, M. & Ikuta, K. Epstein-Barr virus strain variation and cancer. Cancer Sci. 110, 1132\u20131139. https:\/\/doi.org\/10.1111\/cas.13954 (2019).","journal-title":"Cancer Sci."},{"key":"90479_CR43","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.1073\/pnas.94.23.12616","volume":"94","author":"J Levitskaya","year":"1997","unstructured":"Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M. G. Inhibition of ubiquitin\/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U.S.A. 94, 12616\u201312621. https:\/\/doi.org\/10.1073\/pnas.94.23.12616 (1997).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"90479_CR44","doi-asserted-by":"publisher","first-page":"29987","DOI":"10.1074\/jbc.M303977200","volume":"278","author":"MN Holowaty","year":"2003","unstructured":"Holowaty, M. N. et al. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP\/USP7. J. Biol. Chem. 278, 29987\u201329994. https:\/\/doi.org\/10.1074\/jbc.M303977200 (2003).","journal-title":"J. Biol. Chem."},{"key":"90479_CR45","doi-asserted-by":"publisher","first-page":"e0224321","DOI":"10.1128\/mBio.02243-21","volume":"12","author":"D Westhoff Smith","year":"2021","unstructured":"Westhoff Smith, D., Chakravorty, A., Hayes, M., Hammerschmidt, W. & Sugden, B. The Epstein-Barr Virus Oncogene EBNA1 suppresses natural killer cell responses and apoptosis early after infection of Peripheral B cells. mBio 12, e0224321. https:\/\/doi.org\/10.1128\/mBio.02243-21 (2021).","journal-title":"mBio"},{"key":"90479_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. & Kumar, S. Multiple myeloma: diagnosis and treatment. Mayo Clin. Proc. 91, 101\u2013119. https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.007 (2016).","journal-title":"Mayo Clin. Proc."},{"key":"90479_CR47","doi-asserted-by":"publisher","first-page":"e1001151","DOI":"10.1371\/journal.ppat.1001151","volume":"6","author":"S Apcher","year":"2010","unstructured":"Apcher, S., Daskalogianni, C., Manoury, B. & F\u00e5hraeus, R. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathog. 6, e1001151. https:\/\/doi.org\/10.1371\/journal.ppat.1001151 (2010).","journal-title":"PLoS Pathog"},{"key":"90479_CR48","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1126\/science.1088902","volume":"301","author":"Y Yin","year":"2003","unstructured":"Yin, Y., Manoury, B. & F\u00e5hraeus, R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301, 1371\u20131374. https:\/\/doi.org\/10.1126\/science.1088902 (2003).","journal-title":"Science"},{"key":"90479_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/375685a0","volume":"375","author":"J Levitskaya","year":"1995","unstructured":"Levitskaya, J. et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685\u2013688. https:\/\/doi.org\/10.1038\/375685a0 (1995).","journal-title":"Nature"},{"key":"90479_CR50","doi-asserted-by":"publisher","first-page":"1444821","DOI":"10.3389\/fimmu.2024.1444821","volume":"15","author":"S Suzuki","year":"2024","unstructured":"Suzuki, S. et al. Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow. Front. Immunol. 15, 1444821. https:\/\/doi.org\/10.3389\/fimmu.2024.1444821 (2024).","journal-title":"Front. Immunol."},{"key":"90479_CR51","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3389\/fimmu.2017.01658","volume":"8","author":"C M\u00fcnz","year":"2017","unstructured":"M\u00fcnz, C. Epstein-Barr Virus-Specific Immune Control by Innate Lymphocytes. Front. Immunol. 8, 1658. https:\/\/doi.org\/10.3389\/fimmu.2017.01658 (2017).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90479-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90479-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90479-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:07:55Z","timestamp":1740139675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90479-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90479"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90479-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Each of the studies contributing to the GWAS obtained informed consent from study participants and ethical approval for data collection and analysis. Our study complied with all relevant ethical regulations, including the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"6357"}}